Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Institute for Academic Medicine
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp

Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial
Fan, W, Abdelfattah, NS, Uji, A, Lei, J, Ip, M, Sadda, SVR, Wykoff, CC & on behalf of the TREX-AMD Study Group 2018, Graefes Archive for Clinical and Experimental Ophthalmology, pp. 1-8. DOI: 10.1007/s00417-017-3888-2

Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion. Three-Year Randomized DAVE Trial
Brown, DM, Ou, WC, Wong, TP, Kim, RY, Croft, DE & Wykoff, CC 2018, Ophthalmology. DOI: 10.1016/j.ophtha.2017.11.026

Diagnostic and Therapeutic Challenges
Burgess, FR, Radwan, M, Croft, DE & Wykoff, CC 2017, Retina. DOI: 10.1097/IAE.0000000000001549

Positive visual phenomena following implantation of the argus II retinal prosthesis
Sadaka, A, Iqbal, C, Nazari, H, Berry, S, Wykoff, CC, Humayun, MS & Lee, AG 2017, Ophthalmic Surgery Lasers and Imaging Retina, vol 48, no. 12, pp. 1022-1025. DOI: 10.3928/23258160-20171130-11

Intravitreal aflibercept for proliferative diabetic retinopathy
Brown, DM & Wykoff, CC 2017, The Lancet, vol 390, no. 10108. DOI: 10.1016/S0140-6736(17)32445-5

Relationship Between Visual Acuity and Retinal Thickness During Anti–Vascular Endothelial Growth Factor Therapy for Retinal Diseases
Ou, WC, Brown, DM, Payne, JF & Wykoff, CC 2017, American Journal of Ophthalmology, vol 180, pp. 8-17. DOI: 10.1016/j.ajo.2017.05.014

Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study
Fan, W, Wang, K, Ghasemi Falavarjani, K, Sagong, M, Uji, A, Ip, M, Wykoff, CC, Brown, DM, van Hemert, J & Sadda, SVR 2017, American Journal of Ophthalmology. DOI: 10.1016/j.ajo.2017.05.024

Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study
Wykoff, CC, Ou, WC, Brown, DM, Croft, DE, Wang, R, Payne, JF, Clark, WL, Abdelfattah, NS, Sadda, SVR & TREX-AMD Study Group 2017, Kidney International Reports, vol 2, no. 4, pp. 314-321. DOI: 10.1016/j.oret.2016.12.004

Wykoff, CC, Le, RT, Khurana, RN, Brown, DM, Ou, WC, Wang, R, Clark, WL & Boyer, DS 2017, American Journal of Ophthalmology, vol 177, pp. 236-237. DOI: 10.1016/j.ajo.2017.02.024

Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy
Wykoff, CC 2017, Current Opinion in Ophthalmology, vol 28, no. 3, pp. 213-218. DOI: 10.1097/ICU.0000000000000364

Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes
Witkin, AJ, Chang, DF, Jumper, JM, Charles, S, Eliott, D, Hoffman, RS, Mamalis, N, Miller, KM & Wykoff, CC 2017, Ophthalmology, vol 124, no. 5, pp. 583-595. DOI: 10.1016/j.ophtha.2016.11.042

Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial
Wykoff, CC, Ou, WC, Wang, R, Brown, DM, Cone, C, Zamora, D, Le, RT, Sagong, M, Wang, K & Sadda, SVR 2017, Ophthalmology. DOI: 10.1016/j.ophtha.2017.01.049

Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy
Wykoff, CC, Chakravarthy, U, Campochiaro, PA, Bailey, C, Green, K & Cunha-Vaz, J 2017, Ophthalmology, vol 124, no. 4, pp. 440-449. DOI: 10.1016/j.ophtha.2016.11.034

Diabetic retinopathy: A position statement by the American Diabetes Association
Solomon, SD, Chew, E, Duh, EJ, Sobrin, L, Sun, JK, VanderBeek, BL, Wykoff, CC & Gardner, TW 2017, Diabetes Care, vol 40, no. 3, pp. 412-418. DOI: 10.2337/dc16-2641

Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials
Wykoff, CC, Marcus, DM, Midena, E, Korobelnik, JF, Saroj, N, Gibson, A, Vitti, R, Berliner, AJ, Liu, ZW, Zeitz, O, Metzig, C, Schmelter, T & Heier, JS 2017, JAMA ophthalmology, vol 135, no. 2, pp. 107-114. DOI: 10.1001/jamaophthalmol.2016.4912

Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial
Abdelfattah, NS, Al-Sheikh, M, Pitetta, S, Mousa, A, Sadda, SVR, Wykoff, CC, Wykoff, CC, Croft, DE, Brown, DM, Wang, R, Payne, JF, Clark, L, Abdelfattah, NS, Sadda, SVR, Benz, MS, Chen, E, Fish, RH, Johnson, DL, Kim, RY, Major, JC, OMalley, RE, Schefler, AC, Shah, AR, Vance, SK, Wells, JA & Wong, TP 2017, Ophthalmology, vol 124, no. 2, pp. 215-223. DOI: 10.1016/j.ophtha.2016.10.002

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study
Wykoff, CC, Le, RT, Khurana, RN, Brown, DM, Ou, WC, Wang, R, Clark, WL & Boyer, DS 2017, American Journal of Ophthalmology, vol 173, pp. 56-63. DOI: 10.1016/j.ajo.2016.09.029

Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes
Payne, JF, Wykoff, CC, Clark, WL, Bruce, BB, Boyer, DS, Brown, DM & TREX-DME Study Group 2017, Ophthalmology, vol 124, no. 1, pp. 74-81. DOI: 10.1016/j.ophtha.2016.09.021

Treating recurrent retinal detachment due to PVR: This presentation can be a tall order for the surgeon, but the suggestions offered here can make the task less daunting
Wykoff, CC 2017, Retina Today, vol 2017, no. January-February, pp. 32-33.

Khurana, RN, Wykoff, CC, Bansal, AS, Akiyama, K, Palmer, JD, Chen, E, Chang, LK, Major, JC, Wu, C, Wang, R, Croft, DE & Wong, TP 2016, Retina. DOI: 10.1097/IAE.0000000000001307